

## Drug Safety

---

# Studying the Science of Observational Research: Empirical Findings from the Observational Medical Outcomes Partnership

Guest Editor

*Stephen J. W. Evans*

Professor of Pharmacoepidemiology, London School of Hygiene  
and Tropical Medicine, London, UK

Peer Reviewer

*Olaf H. Klungel*

Associate Professor, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands

This supplement was sponsored by the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration.

At the time of publication of this supplement, the Observational Medical Outcomes Partnership has been transitioned from the Foundation for the National Institutes of Health into the Innovation in Medical Evidence Development and Surveillance program at the Reagan-Udall Foundation for the Food and Drug Administration.

*Conflicts of Interest: Stephen J.W. Evans has received travel funding from the FNIH to travel to the OMOP symposium and received a fee from FNIH for the review of a protocol for OMOP. Olaf H. Klungel has received a small honorarium for peer reviewing the supplement to cover out-of-pocket expenses, and has also received funding for the IMI-PROTECT project from the Innovative Medicines Initiative Joint Undertaking (<http://www.imi.europa.eu>) under Grant Agreement no 115004, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution.*